Encontra-se aberta a submissão de propostas para a Call 16 da IMI-2, até ao dia 24 de outubro de 2018, para os seguintes tópicos:

• Topic 1: Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for tuberculosis (TB) that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
• Topic 2: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
• Topic 3: Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
• Topic 4: Determination of gepotidacin levels in tonsils and prostatic tissue
• Topic 5: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
• Topic 6: Functional Ethionamide boosters: a novel combination for tuberculosis therapy
• Topic 7: Intravenous treatments of serious infections (urinary tract infections (UTI), intra-abdominal infections (IAI) & hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)

O Orçamento para esta Call vem definido da seguinte forma: 46.900.000 € financiados pelo IMI2 e o restante será estebelecido pelas empresas e Membros Associados da EFPIA baseado nas propostas que forem estabelecidas.

Conheça os concursos lançados anteriormente e os projetos já financiados!

Website da IMI-2: http://www.imi.europa.eu/content/home

Publicado: 18 de julho de 2018